摘要
目的探讨盐酸曲美他嗪治疗缺血性心肌病慢性心力衰竭的临床效果。方法将我院2012年10月—2014年10月收治的84例缺血性心肌病慢性心力衰竭病人随机分为对照组(n=42)和治疗组(n=42),两组均给予心力衰竭的常规治疗措施,仅治疗组在此基础上加用盐酸曲美他嗪(20 mg)治疗每日3次。观察两组在治疗前、治疗6个月后左室射血分数(LVEF)、E/A值,收缩末期内径(LVESD)、舒张末期内径(LVEDD)及血浆N末端脑钠肽前体(NT-pro BNP)水平。结果 6个月后,对照组E/A比值、LVESD及LVEDD与入院时相比无统计学意义,但LVEF、血清NT-pro BNP的随访结果与入院时相比有统计学意义(P<0.05)。治疗组LVEDD与入院时相比无统计学意义,但LVEF、E/A比值、LVESD及血清NT-pro BNP随访结果与入院时相比有统计学意义(P<0.05)。6个月时组间比较,两组除LVEDD无统计学意义外,LVEF、E/A值、LVESD及血清NT-pro BNP的随访结果有统计学意义。结论盐酸曲美他嗪能够明显改善缺血性心肌病慢性心力衰竭病人的心脏重构及左室射血功能。
Objective To evaluate the therapeutic effect of trimetazidine（ TMZ） in the treatment of patients with ischemic cardiomyopathy heart failure. Methods Ninty-eight patients with ischemic cardiomyopathy heart failure were randomly divided into two groups： control group（n =42） treated with routine treatment,and treatment group（n = 42） treated with routine treatment plus TMZ for 6 months. The left ventricular ejection fraction（ LVEF）,E / A ratio,left ventricular end-systolic diameter（ LVESD）,left ventriculer end-diastolic diameters（ LVEDD）,Nterminal pro-brain natriuretic peptide（ NT-pro BNP） levels were observed. Results After treatment of 6 months,there was no statistical significance in the echocardiography parameters such as E / A ratio,LVESD and LVEDD in control group,but there was statistical significance in LVEF and NT-pro BNP in control group（P〈0. 05）. LVEF,E / A ratio,LVESD and NT-pro BNP were improved significantly in treatment group（P〈0. 05）. There was statistical significance in LVEF,E/A ratio and NT-pro BNP between two groups. Conclusion TMZ can inhibit cardiac remodeling and improve cardiac function in patients with ischemic cardiomyopathy heart failure.
出处
《中西医结合心脑血管病杂志》
2016年第7期676-678,共3页
Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
